Ar­gos Ther­a­peu­tics slash­es staff in the wake of the lat­est can­cer vac­cine flop

Two weeks af­ter Ar­gos Ther­a­peu­tics saw its Phase III tri­al of its per­son­al­ized can­cer vac­cine ro­ca­pulden­cel-T end in dis­as­ter, the Durham, NC-based biotech is tak­ing the ob­vi­ous next step, cut­ting its work­force by 38% as it re­groups and looks for a path for­ward.

Ar­gos filed an 8-K ex­plain­ing that the board de­cid­ed on Wednes­day to lay off 46 staffers, leav­ing a work­force of 76 em­ploy­ees. HR chief Joan C. Win­ter­bot­tom is join­ing the ex­o­dus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER